Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has worked diligently but unsuccessfully to produce an one-time therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination treatment in the curing of multi-drug-resistant HIV happen to be closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of the last several shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What to be able to Do When It is Too Good To Be True?”, set away the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a very marketing image in the Uptick Newswire employment interview that I came away with an inadequate opinion of the business.

Irony of irony, the bad opinion of mine of the business enterprise has grown steadily, though the disappointment hasn’t been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger at the moment still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much storied treatment (which I shall mean as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the expertise and also associated intellectual property coming from Progenics to CytoDyn, as well as roughly twenty five million mg of bulk drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 huge number of) as well as the first new drug application endorsement ($5 million), and even royalty payments of 5 % of net sales after commercialization.

Since that point in time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous indications and many therapies, it has this single remedy and a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially advantageous therapy in dozens of indications.

Its opening banner on its website (below) shows an active business with diverse interests albeit centered on leronlimab, several illness types, multiple presentations in addition to multiple publications.

Can all this be smoke cigarettes and mirrors? That is a question I have been asking myself with the really beginning of the interest of mine in this particular business. Judging by the multiples of a huge number of several remarks on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am much from alone in this question.

CytoDyn is a traditional battleground, or possibly some could say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *